VIA
AMRX icon

Virtus Investment Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History

Virtus Investment Advisers’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-34,510
Closed -$273K – 487
2024
Q4 		$273K Hold
34,510
– – 0.21% 152
2024
Q3 		$287K Hold
34,510
– – 0.23% 146
2024
Q2 		$219K Hold
34,510
– – 0.19% 172
2024
Q1 		$209K Sell
34,510
-25,200
-42% -$142K 0.15% 188
2023
Q4 		$362K Hold
59,710
– – 0.27% 117
2023
Q3 		$252K Buy
59,710
+15,230
+34% +$56.8K 0.17% 148
2023
Q2 		$138K Hold
44,480
– – 0.09% 220
2023
Q1 		$61.8K Buy
+44,480
New +$88.6K 0.04% 264

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Virtus Investment Advisers's AMRX Position: Q1 2025 in Review

Virtus Investment Advisers sold out of Amneal Pharmaceuticals (AMRX) in Q1 2025, closing a stake of 34,510 shares — an estimated $273K sold.

Virtus Investment Advisers first reported a position in AMRX in Q1 2023 and held it in 8 quarters. The position peaked at $362K in Q4 2023. 237 funds tracked by Wall St. Rank hold AMRX as of Q1 2025.

  • Virtus Investment Advisers reported no remaining Amneal Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus Investment Advisers sold 34,510 Amneal Pharmaceuticals shares in Q1 2025, an estimated $273K.
  • Virtus Investment Advisers first reported a position in Amneal Pharmaceuticals in Q1 2023 and held it in 8 quarters.
  • Virtus Investment Advisers's Amneal Pharmaceuticals position peaked at $362K in Q4 2023.
  • 237 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2025.

Based on Virtus Investment Advisers's 13F filing for Q1 2025, filed 15 May 2025.